Tactile Medical Reports Strong Q4 & FY2025 Results, Acquires LymphaTech for Strategic Growth

summarizeSummary

Tactile Medical announced strong Q4 and full-year 2025 financial results, including double-digit revenue growth and increased profitability, alongside a strategic acquisition of LymphaTech to enhance its lymphedema solutions.

check_boxKey Events

• Strong Q4 & FY2025 Financial Performance

  Reported a 21% year-over-year revenue increase to $103.6 million in Q4 2025 and a 12% increase to $329.5 million for the full year, with improved gross margins and Adjusted EBITDA.

• Positive 2026 Financial Outlook

  Provided guidance for full-year 2026 revenue between $357 million and $365 million (8-11% growth) and Adjusted EBITDA between $49 million and $51 million.

• Strategic Acquisition of LymphaTech

  Acquired LymphaTech Inc. for an upfront cash payment of $6.8 million, expanding its lymphedema solutions portfolio with digital 3D scanning technology for disease identification and monitoring.

• Solid Balance Sheet and Capital Management

  Ended 2025 with $83.4 million in cash, having repaid its $26.3 million term loan and repurchased $26.5 million in stock.

auto_awesomeAnalysis

Tactile Systems Technology Inc. reported robust financial performance for the fourth quarter and full year 2025, demonstrating double-digit revenue growth and improved profitability. This strong operational backdrop is further enhanced by the strategic acquisition of LymphaTech, which expands the company's lymphedema solutions portfolio with advanced digital 3D scanning technology. The acquisition, while modest in upfront cost, is expected to bolster R&D capabilities and support future growth in disease identification and therapy. The positive financial outlook provided for 2026 reinforces the company's continued growth trajectory and solidifies its market position.